ABT Abbott Laboratories

  1. Stocks
  2. Healthcare
  3. NYSE: ABT

Price (delayed)

$109.05

Market cap

$188.7B

P/E Ratio

35.18

Dividend/share

$2.48

EPS

$3.1

Enterprise value

$216.2B

?
Relative Growth: Rel. Growth: 42
Relative Strength: Rel. Strength: 41
Relative Valuation: Rel. Valuation: 35
Relative Profitability: Rel. Profitability: 61

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses ...

Highlights
The gross profit has increased by 9% year-on-year and by 3.9% since the previous quarter
The revenue has grown by 8% YoY and by 3.2% from the previous quarter
Abbott Laboratories's debt has surged by 143% YoY but it has decreased by 4.2% QoQ
The EPS has plunged by 61% YoY and by 14% from the previous quarter
Abbott Laboratories's net income has shrunk by 61% YoY and by 14% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: http://www.abbott.com
Peers: JNJ PFE MDT TMO

Key stats

What are the main financial stats of ABT

ABT stock price

How has the Abbott Laboratories stock price performed over time
Intraday
3.17%
1 week
4.36%
1 month
14.31%
1 year
-14.33%
YTD
-12.96%
QTD
20.18%

Financial performance

How have Abbott Laboratories's revenue and profit performed over time
Revenue
$46.59B
Gross profit
$26.37B
Operating income
$7.35B
Net income
$5.43B
Gross margin
56.6%
Net margin
11.6%
Abbott Laboratories's net margin has shrunk by 64% YoY and by 17% QoQ
Abbott Laboratories's net income has shrunk by 61% YoY and by 14% QoQ
The gross profit has increased by 9% year-on-year and by 3.9% since the previous quarter
Abbott Laboratories's operating margin has decreased by 9% YoY and by 8% from the previous quarter

Price vs fundamentals

How does ABT's price correlate with its fundamentals

Growth

What is Abbott Laboratories's growth rate over time

Valuation

What is Abbott Laboratories stock price valuation
ABT P/E details
P/E
35.18
P/B
3.67
P/S
4.07
EV/EBIT
26.12
EV/EBITDA
18.44
EV/Sales
4.64
The EPS has plunged by 61% YoY and by 14% from the previous quarter
ABT's P/E is 26% above its last 4 quarters average of 27.1 and 22% above its 5-year quarterly average of 27.9
ABT's price to book (P/B) is 26% lower than its 5-year quarterly average of 4.8 and 6% lower than its last 4 quarters average of 3.8
ABT's P/S is 16% below its 5-year quarterly average of 4.7 and 10% below its last 4 quarters average of 4.4
The revenue has grown by 8% YoY and by 3.2% from the previous quarter

Efficiency

How efficient is Abbott Laboratories business performance
Abbott Laboratories's return on assets has shrunk by 68% YoY and by 19% QoQ
ABT's ROE has plunged by 65% YoY and by 14% from the previous quarter
The ROIC has contracted by 24% YoY and by 13% from the previous quarter
The ROS has contracted by 9% YoY and by 7% from the previous quarter

Dividends

What is ABT's dividend history
Dividend details
DPS
$2.48
Dividend yield
2.27%
Payout ratio
80%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Abbott Laboratories financials performed over time
The total assets is 90% more than the total liabilities
Abbott Laboratories's total liabilities has soared by 73% YoY
ABT's quick ratio is down by 30% year-on-year and by 4.8% since the previous quarter
Abbott Laboratories's debt is 37% lower than its equity
Abbott Laboratories's debt has surged by 143% YoY but it has decreased by 4.2% QoQ
Abbott Laboratories's debt to equity has soared by 142% YoY but it has decreased by 3.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.